RSK inhibition with BI-D1870 and BRD7389 resulted in a significant reduction of protein synthesis and proliferation in dual-resistant melanoma cell lines to BRAF and MEK inhibitors [102]. The gene discussed is MAP2K7; the disease is melanoma.